CME: Emerging Treatment Considerations in Metastatic Urothelial Cancer

Keeping Pace: Emerging Treatment Considerations in Metastatic Urothelial Cancer

Keeping Pace: Emerging Treatment Considerations in Metastatic Urothelial Cancer
RestartResume

What treatment plans should you be using for your patients with metastatic urothelial cancer, the sixth most common malignancy in the US?

Available credits: 0.25

Time to complete: 15 Minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    The treatment of urothelial carcinoma, the most common type of bladder cancer, has historically been limited to platinum-based chemotherapy; however, the majority of patients will relapse. And while immunotherapy has offered survival benefits to patients, not all patients respond to immune checkpoint inhibitors. That’s why it’s so important for clinicians to understand the current and emerging treatment strategies for patients with metastatic urothelial cancer, as this activity explains.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:

    Peter H. O’Donnell, MD
    Associate Professor of Medicine
    University of Chicago
    Chicago, IL

    Consulting Fees: Merck
    Research Funding (directly to University of Chicago): Acerta Pharma, AstraZeneca/MedImmune, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech/Roche, Janssen, Merck, Seattle Genetics
    Honoraria: Astellas Pharma, Atheneum Partners, Dedham Group, FirstWord Publication, Genentech/Roche, Health Advances, Janssen, Merck, OncLive, Schlesinger Associates, Seattle Genetics
    Travel, Accommodations, Expenses: Genentech/Roche, Janssen, Merck, Seattle Genetics/Astellas
    Other: Janssen, Nektar

    Faculty:

    Daniel P. Petrylak, MD
    Professor of Medicine (Medical Oncology) and of Urology
    Yale School of Medicine
    New Haven, CT

    Consultant Fees: Ada Cap (Advanced Accelerator Applications), Amgen, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, Boehringer Ingelheim, Bristol Myer Squibb, Clovis, Eli Lilly, Exelixis, Incyte, Janssen, Pfizer, Pharmacyclics, Roche Laboratories, Seattle Genetics, Urogen
    Grant Support: Ada Cap (Advanced Accelerator Applications), Astellas, AstraZeneca, Bayer, Bristol Myer Squibb, Clovis, Eli Lilly, Endocyte, Genentech, Innocrin, MedImmune, Merck, Novartis, Pfizer, Progenics, Roche Laboratories, Sanofi Aventis, Seattle Genetics
    Ownership interest/investment: Bellicum

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Barry A. Feidel, PhD has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP  has nothing to disclose
    • Tricia O’Leary has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Compare the safety and efficacy of currently available treatment options for metastatic urothelial cancer.
    • Identify and assess the therapeutic potential of newly emergent agents for the treatment of metastatic urothelial cancer.
  • Target Audience

    This activity is designed to meet the educational needs of Oncologists and Urologists, NPs/PAs, Nurses, and Pathologists.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from SeaGen and Astellas.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

Register

We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free